Discounted Cash Flow Rating

Strong Sell

Return on Equity Rating

Strong Buy

Debt to Equity Rating

Strong Sell

Price to Earnings Rating

Neutral

Analyst Rating

Sell

Upgrade To View Simple Moving Average Rating

Upgrade

Upgrade To Get Access

Upgrade To View Exponential Moving Average Rating

Upgrade

Upgrade To Get Access

Upgrade To View Relative Strength Index Rating

Upgrade

Upgrade To Get Access

Upgrade To View Standard Deviation Rating

Upgrade

Upgrade To Get Access

Upgrade To View Williams %R Rating

Upgrade

Upgrade To Get Access

Upgrade To View Average Directional Index Rating

Upgrade

Upgrade To Get Access

Upgrade To View Insider Trading Rating

Upgrade

Upgrade To Get Access

Wall Street Data Solutions Rating

Neutral

B

Qualigen Therapeutics, Inc. Common Stock (QLGN)

Pharmaceutical Preparations

https://www.qualigeninc.com

Qualigen Therapeutics Inc is a biotechnology company focused on the development and commercialization of novel therapeutic products for the treatment of cancer and infectious diseases using nanoparticle coating technology. It is a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug designation, while also commercializing diagnostics. The Company has viewed its operations and managed its business in one segment operating mainly within the United States and Israel.

2042 CORTE DEL NOGAL, CARLSBAD
CALIFORNIA, CA

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

05/26/2020

Market Cap

2,363,088

Shares Outstanding

5,180,000

Weighted SO

5,181,058

Total Employees

N/A

Upcoming Earnings

N/A

Similar Tickers

ZVSA --.--%

IMMX --.--%

PHIO --.--%

ATNF --.--%

NAVB --.--%

ENOB --.--%

TCON --.--%

ARDS --.--%

ENTX --.--%

Beta

0.0750

Last Div

0.0000

Range

0.145-1.21

Chg

-0.0026

Avg Vol

12946001

Mkt Cap

2363088

Exch

NASDAQ

Country

US

Phone

760 918 9165

DCF Diff

0.3710

DCF

-0.1769

Div Yield

0.0000

P/S

0.2975

EV Multiple

-0.5576

P/FV

0.0000

Div Yield %

0.0000

P/E

-0.1519

PEG

-0.0028

Payout

0.0000

Current Ratio

0.1111

Quick Ratio

0.1111

Cash Ratio

0.0247

DSO

0.0000

DIO

0.0000

Op Cycle

0.0000

DPO

113.5800

CCC

-113.5800

Gross Margin

0.2500

Op Margin

-1.0329

Pretax Margin

-1.1602

Net Margin

-1.2253

Eff Tax Rate

-0.0453

ROA

-18.2134

ROE

5.3585

ROCE

1.9180

NI/EBT

1.0561

EBT/EBIT

1.1232

EBIT/Rev

-1.0329

Debt Ratio

4.2285

D/E

0.0000

LT Debt/Cap

0.0000

Total Debt/Cap

1.0000

Int Coverage

-8.1790

CF/Debt

-2.4452

Equity Multi

0.0000

Rec Turnover

0.0000

Pay Turnover

3.2136

Inv Turnover

0.0000

FA Turnover

0.0000

Asset Turnover

14.8638

OCF/Share

-0.7267

FCF/Share

-0.6943

Cash/Share

0.0156

OCF/Sales

-0.6956

FCF/OCF

0.9554

CF Coverage

-2.4452

ST Coverage

-2.4452

CapEx Coverage

-22.4230

Div&CapEx Cov

-22.4230

P/BV

0.0000

P/B

0.0000

P/S

0.2975

P/E

-0.1519

P/FCF

-0.4476

P/OCF

-0.2675

P/CF

-0.2675

PEG

-0.0028

P/S

0.2975

EV Multiple

-0.5576

P/FV

0.0000

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. Nov 07, 08:30 Qualigen Therapeutics Announces First Patient Dosed in the Phase 1a Clinical Trial of QN-302 for Treatment of Advanced or Metastatic Solid Tumors

Revenue Product Segmentation